Document Detail

Effect of ranitidine on soluble interleukin 2 receptors and CD8 molecules in surgical patients.
MedLine Citation:
PMID:  7827929     Owner:  NLM     Status:  MEDLINE    
The effect of perioperative immunomodulation with the H2-receptor antagonist ranitidine on postoperative changes in soluble interleukin (IL) 2 receptor and soluble CD8 levels was assessed in 24 patients undergoing major elective abdominal surgery. Eleven patients were randomized to receive intravenous ranitidine 100 mg twice daily for 4 days from skin incision, followed by oral ranitidine 150 mg twice daily for a further 5 days; 13 control patients received no ranitidine. Routine blood analysis, clinical data, duration of surgery, anaesthesia, antibiotic prophylaxis and perioperative blood transfusion were similar in the two groups. Serum concentrations of soluble IL-2 receptor and CD8 were measured before operation (day 0) and in the morning of postoperative days 1, 3 and 9 using commercial enzyme-linked immunosorbent assay kits. In patients treated with ranitidine, the serum level of soluble IL-2 receptor increased from day 0 to day 9 (P < 0.01); in control patients it decreased from day 0 to day 1, did not change significantly by day 3 and increased by day 9. The change from day 0 to day 1 was significantly different between the two groups (P < 0.01). Five of the 13 control patients developed postoperative infectious complications. No significant differences were shown in soluble CD8 concentration during the postoperative period. The postoperative change in soluble IL-2 receptor level may reflect lymphocyte activation status; ranitidine appears to promote activation of mainly CD4-positive lymphocytes since serum levels of CD8 were unchanged. Ranitidine may, therefore, improve immune function during major surgery.
H J Nielsen; T Mynster; S Jensen; J Hammer; H Nielsen
Related Documents :
23434569 - Clustering of hand osteoarthritis progression and its relationship to progression of os...
2863089 - A multi-centre, double-blind parallel trial of bromazepam ('lexotan') and lorazepam to ...
8881809 - Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prosp...
2979209 - Intragastric ph monitoring in acute upper gastrointestinal bleeding and the effect of i...
10448449 - Treatment of neuroleptic-induced akathisia with the 5-ht2 antagonist mianserin. double-...
7861219 - Prospective double-blind placebo-controlled randomized trial on the use of ranitidine i...
17640339 - Short-term and one-year outcome of infective endocarditis in adult patients treated in ...
23839609 - Failure of anti-tnf therapy to reactivate previously septic prosthetic joints.
12141769 - Antibiotic prophylaxis in rhinosurgery.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The British journal of surgery     Volume:  81     ISSN:  0007-1323     ISO Abbreviation:  Br J Surg     Publication Date:  1994 Dec 
Date Detail:
Created Date:  1995-02-23     Completed Date:  1995-02-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372553     Medline TA:  Br J Surg     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1747-51     Citation Subset:  AIM; IM    
Department of Surgical Gastroenterology 235, Hvidovre University Hospital, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abdomen / surgery
Administration, Oral
Antigens, CD8 / blood*
Injections, Intravenous
Middle Aged
Postoperative Period
Preoperative Care
Ranitidine / administration & dosage,  pharmacology*
Receptors, Interleukin-2 / metabolism*
Surgical Procedures, Elective
Time Factors
Reg. No./Substance:
0/Antigens, CD8; 0/Receptors, Interleukin-2; 66357-35-5/Ranitidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis ...
Next Document:  Multi-agent therapy in the treatment of sepsis-induced microvascular injury.